FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19 PREVENTION & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19 Page 1/2 PREVENTION PROTOCOL Behavioral Prevention WEAR MASKS Wear a cloth, surgical, or N95 mask when in confined, poorly venti- lated, crowded indoor spaces with non- household members. lvermectin1 Vitamin D3 Vitamin C Quercetin Zinc Melatonin Gargle mouthwash Chronic Prevention 0.2 mg/kg per dose (take with or after a meal) — twice a week for as long as disease risk is elevated in your community Post COVID-19 Exposure Prevention2 0.4 mg/kg per dose (take with or after a meal) — one dose today, repeat after 48 hours 1,000–3,000 IU/day 500–1,000 mg twice a day 250 mg/day 30–40 mg/day (elemental zinc) 6 mg before bedtime (causes drowsiness) 2 x daily – gargle (do not swallow) antiseptic mouthwash with cetylpyri­ dinium chloride (e.g. ScopeTM, ActTM, CrestTM), ListerineTM with essential oils, or povidone/iodine 1 % solution as alternative. EARLY OUTPATIENT PROTOCOL3 lvermectin1 Fluvoxamine4 Nasal/oral rinse Vitamin D3 Vitamin C Quercetin Zinc Melatonin Aspirin Pulse Oximeter 0.4–0.6 mg/kg per dose (take with or after a meal) — one dose daily, take for 5 days or until recovered Use upper dose range if: 1) in regions with aggressive variants (e.g. “Delta” variant); 2) treatment started on or after day 5 of symptoms or in pulmonary phase; or 3) multiple comorbidities/risk factors. 50 mg twice daily for 10–14 days Add to ivermectin if: 1) minimal response after 2 days of ivermectin; 2) in regions with more aggressive variants; 3) treatment started on or after day 5 of symptoms or in pulmonary phase; or 4) numerous comorbidities/risk factors. Avoid if patient is already on an SSRI. 3 x daily – gargle (do not swallow) antiseptic mouthwash with cetylpyridi­ nium chloride (e.g. ScopeTM, ActTM, CrestTM), ListerineTM with essential oils, or povidone/iodine 1 % solution as alternative. Nasal rinse instructions below.5 4,000 IU/day 500–1,000 mg twice a day 250 mg twice a day 100 mg/day (elemental zinc) 10 mg before bedtime (causes drowsiness) 325 mg/day (unless contraindicated) Monitoring of oxygen saturation is recommended (for instructions see page 2) KEEP DISTANCE Until the end of the COVID-19 crisis, we recommend keeping a minimum distance of approx. 2 m / 6 feet in public from people who are not from your own household. 1 The dosing may be updated as further scientific studies emerge. The safety of ivermectin in pregnancy has not been definitively established. Use in the 1st trimester should be discussed with your doctor. 2 To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask 3 For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treatment Protocol for COVID-19 on www.flccc.net 4 Some individuals who are prescribed fluvoxamine experience acute anxiety which needs to be carefully moni- tored for and treated by the prescribing clinician to prevent rare escalation to suicidal or violent behavior. 5 Nasal rinse – 3 x daily. Use 10 % povidone/iodine wound wash. Take 1 ml (1/4 tsp) mix with 9 ml saline solution (2 tsp). Use nasal irrigation bottle or syringe. Please regard our disclaimer and further information on page 2 of this document. WASH HANDS We recommend, after a stay during and after outings from home (shopping, subway etc.), a thorough hand clean- ing (20–30 sec. with soap), or also to use a hand disinfectant in between. flccc.net © 2020–2021 FLCCC Alliance · I-MASK+ Protocol · Version 12 · August 11, 2021 Layout & typesetting by raumfisch.de/sign

PREVENTION & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19 IVERMECTIN Summary of the Clinical Trials Evidence for Ivermectin in COVID­19 Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and anti- inflammatory properties in laboratory studies. In the past 4 months, numerous, con- trolled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin. Our comprehensive scientific review of these referenced trials on ivermectin can be found on www.flccc.net/flccc-ivermectin-in-the- prophylaxis-and-treatment-of-covid-19/ For a quick overview, a One-page Summary of our review on ivermectin can be found on www.flccc.net/flccc-ivermectin-summary FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19 Page 2/2 Body weight conversion (kg/lb) for ivermectin dose in prevention and treatment of COVID­19 Body weight Conversion (1 kg ≈ 2.2 lbs) (doses calculated per upper end of weight range) Dose 0.2 mg/kg ≈ 0.09 mg/lb (Each tablet = 3 mg; doses rounded to nearest half tablet above) 70–90 lb 91–110 lb 111–130 lb 131–150 lb 151–170 lb 171–190 lb 191–210 lb 211–230 lb 231–250 lb 251–270 lb 271–290 lb 291–310 lb 32–40 kg 41–50 kg 51–59 kg 60–68 kg 69–77 kg 78–86 kg 87–95 kg 96–104 kg 105–113 kg 114–122 kg 123–131 kg 132–140 kg 8 mg 10 mg 12 mg 13.5 mg 15 mg 16 mg 18 mg 20 mg 22 mg 24 mg 26 mg 28 mg (3 tablets = 9 mg) (3.5 tablets) (4 tablets) (4.5 tablets) (5 tablets) (5.5 tablets) (6 tablets) (7 tablets = 21 mg) (7.5 tablets=22.5 mg) (8 tablets) (9 tablets = 27 mg) (9.5 tablets=28.5 mg) Pulse Oximeter (usage instructions) In symptomatic patients, monitoring with home pulse oximetry is recommended (due to asymptomatic hypoxia). The limitations of home pulse oximeters should be recognized, and validated de- vices are preferred. Multiple readings should be taken over the course of the day, and a downward trend should be regarded as ominous. Baseline or ambulatory desaturation < 94% should prompt hospital admission. The following guidance is suggested: – Use the index or middle finger; avoid the toes or ear lobe. – Only accept values associated with a strong pulse signal. – Observe readings for 30–60 seconds to identify the most common value. – Remove nail polish from the finger on which measurements are made. – Warm cold extremities prior to measurement. DISCLAIMER The I-Mask+ Prevention & Early Outpatient Treatment Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19 are solely for educational purposes regarding potentially beneficial therapies for COVID-19. Never disregard professional medical advice because of something you have read on our website and releases. It is not intended to be a substitute for profes- sional medical advice, diagnosis, or treatment in regards to any patient. Treatment for an individual patient should rely on the judgement of your physician or other qualified health provider. Always seek their advice with any questions you may have regard- ing your health or medical condition. For an overview of the developments in prevention and treatment of COVID­19, please visit flccc.net/covid­19­protocols ! Please check our homepage regularly for updates of our COVID­19 Protocols. New medications may be added and/or dose changes to existing medications may be made as further scientific studies emerge! flccc.net © 2020–2021 FLCCC Alliance · I-MASK+ Protocol · Version 12 · August 11, 2021 Layout & typesetting by raumfisch.de/sign

One dose for 3-5 days then twice a week if you have symptoms. Take your 50mg Zinc, 1500-2000IU vitamin C, 5000IU of D3 and 500mg Quecertin daily.

Some of the information cut out. Look up FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19

I gave my horse a full dose and then a second dose 48 hrs later.